Blonanserin

AD 5423

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Wakatabe H, Ochiai K, Murasaki M, et al. Phase I clinical study of AD-5423, a new antipsychotic drug with D2 and S2 antagonist activity. Neuropsychopharmacology 1994 May; 10 Suppl. Pt 2: 192
Google Scholar
Murasaki M. Phase II study results of AD-5423, a newly synthesized SDA neuroleptic in Japan. Psychopharmacol Bull 1997; 33 No. 3: 560
Google Scholar
Oka M, Noda Y, Ochi Y, et al. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties. J Pharmacol Exp Ther 1993 Jan; 264: 158–65
PubMed CAS Google Scholar
Noda Y, Kurumiya S, Miura Y, et al. Comparative study of 2-(4-ethyl-1-piperazinyl)-4-(fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b] pyridine (AD-5423) and haloperidol for their pharmacological activities related to antipsychotic efficacy and/or adverse side-effects. J Pharmacol Exp Ther 1993 May; 265: 745–51
PubMed CAS Google Scholar

Blonanserin. Drugs R&D 2, 49–50 (1999). https://doi.org/10.2165/00126839-199902010-00014

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.